GlassScriptPhysician profile
Johndra M Mcneely
NPI 1417186495
$6,787.41
in general payments reported to CMS, 2019-2025
26 companies · $1,033 in 2025
The $1,033 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,163 · 2020: $253 · 2021: $740 · 2022: $1,260 · 2023: $1,376 · 2024: $962 · 2025: $1,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,128 · Entertainment: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,128.45 |
| Entertainment | $242.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,609.05 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Sun Pharmaceutical Industries INC. | $816.23 | 2019-2025 | Cequa |
| Alcon Vision LLC | $552.59 | 2019-2025 | Total30, Simbrinza, Rocklatan |
| Optos, INC. | $433.03 | 2019-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Biotissue Holdings INC. | $333.31 | 2023-2025 | |
| Bausch & Lomb Americas INC. | $315.39 | 2022-2025 | Infuse, Btod |
| Dompe US, INC. | $267.78 | 2024-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $264.18 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $209.20 | 2019-2025 | |
| Maculogix, INC. | $197.08 | 2019 | |
| Oyster Point Pharma, INC. | $182.66 | 2022-2025 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $170.08 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $155.88 | 2022 | |
| Mallinckrodt Hospital Products INC. | $121.87 | 2023 | Acthar |
| Novartis Pharmaceuticals Corporation | $121.39 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $120.00 | 2023 | Tepezza |
| Amgen INC. | $118.52 | 2025 | Tepezza |
| Shire North American Group INC | $111.83 | 2019 | |
| Glaxosmithkline, LLC. | $107.95 | 2022 | |
| Abbvie INC. | $103.56 | 2022-2023 | Lumigan, Vuity, Alphagan P |
| Lkc Technologies, INC. | $102.73 | 2024 | |
| Allergan, INC. | $95.62 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $91.79 | 2019 | |
| Integra Lifesciences Corporation | $85.32 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $57.58 | 2021 | |
| Harrow Eye, LLC | $42.79 | 2025 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johndra Mcneely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.